In preliminary data from the first-in-human clinical trial of CART-EGFRvIII in patients with recurrent GBM expressing EGFRvIII, Dr. Maus’ group found that infusion of CART-EGFRvIII cells is safe, without evidence of off-tumor toxicity such as cross-reactivity to wild type EGFR. Although they observed trafficking of CAR T cells into the…